153 related articles for article (PubMed ID: 15457132)
41. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
[TBL] [Abstract][Full Text] [Related]
42. Cationic porphyrins and analogues as new DNA topoisomerase I and II inhibitors.
Shuai L; Wang S; Zhang L; Fu B; Zhou X
Chem Biodivers; 2009 Jun; 6(6):827-37. PubMed ID: 19551725
[TBL] [Abstract][Full Text] [Related]
43. Deoxyamphimedine, a pyridoacridine alkaloid, damages DNA via the production of reactive oxygen species.
Marshall KM; Andjelic CD; Tasdemir D; Concepción GP; Ireland CM; Barrows LR
Mar Drugs; 2009 May; 7(2):196-209. PubMed ID: 19597581
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and biological evaluation of N-substituted benzo[c]phenanthrolines and benzo[c]phenanthrolinones as antiproliferative agents.
Genès C; Lenglet G; Depauw S; Nhili R; Prado S; David-Cordonnier MH; Michel S; Tillequin F; Porée FH
Eur J Med Chem; 2011 Jun; 46(6):2117-31. PubMed ID: 21435753
[TBL] [Abstract][Full Text] [Related]
45. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
46. Topoisomerases, new targets in cancer chemotherapy.
Zijlstra JG; de Jong S; de Vries EG; Mulder NH
Med Oncol Tumor Pharmacother; 1990; 7(1):11-8. PubMed ID: 2160032
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
48. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
49. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
50. Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.
Aoyagi Y; Kobunai T; Utsugi T; Wierzba K; Yamada Y
Jpn J Cancer Res; 2000 May; 91(5):543-50. PubMed ID: 10835500
[TBL] [Abstract][Full Text] [Related]
51. Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
Park S; Thapa Magar TB; Kadayat TM; Lee HJ; Bist G; Shrestha A; Lee ES; Kwon Y
Eur J Med Chem; 2017 Feb; 127():318-333. PubMed ID: 28068603
[TBL] [Abstract][Full Text] [Related]
52. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships.
Constantinou A; Mehta R; Runyan C; Rao K; Vaughan A; Moon R
J Nat Prod; 1995 Feb; 58(2):217-25. PubMed ID: 7769390
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and biological evaluation of novel carbazole-rhodanine conjugates as topoisomerase II inhibitors.
Jiang H; Zhang WJ; Li PH; Wang J; Dong CZ; Zhang K; Chen HX; Du ZY
Bioorg Med Chem Lett; 2018 May; 28(8):1320-1323. PubMed ID: 29545100
[TBL] [Abstract][Full Text] [Related]
54. Effects of two distamycin-ellipticine hybrid molecules on topoisomerase I and II mediated DNA cleavage: relation to cytotoxicity.
Riou JF; Grondard L; Naudin A; Bailly C
Biochem Pharmacol; 1995 Jul; 50(3):424-8. PubMed ID: 7646545
[TBL] [Abstract][Full Text] [Related]
55. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
56. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
57. Substituted 2-arylquinazolinones: Design, synthesis, and evaluation of cytotoxicity and inhibition of topoisomerases.
Khadka DB; Tran GH; Shin S; Nguyen HT; Cao HT; Zhao C; Jin Y; Van HT; Chau MV; Kwon Y; Le TN; Cho WJ
Eur J Med Chem; 2015 Oct; 103():69-79. PubMed ID: 26334499
[TBL] [Abstract][Full Text] [Related]
58. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.
Gudkov AV; Zelnick CR; Kazarov AR; Thimmapaya R; Suttle DP; Beck WT; Roninson IB
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3231-5. PubMed ID: 8386368
[TBL] [Abstract][Full Text] [Related]
59. Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents.
Makhey D; Li D; Zhao B; Sim SP; Li TK; Liu A; Liu LF; LaVoie EJ
Bioorg Med Chem; 2003 Apr; 11(8):1809-20. PubMed ID: 12659767
[TBL] [Abstract][Full Text] [Related]
60. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
Abdel-Aziz M; Park SE; Abuo-Rahma Gel-D; Sayed MA; Kwon Y
Eur J Med Chem; 2013 Nov; 69():427-38. PubMed ID: 24090914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
